Switzerland Archives

News and Trends 5 Mar 2015

Novartis announces completion of transactions with GSK

Completes transactions with GSK including: acquisition of GSK oncology portfolio, creation of Consumer Healthcare joint venture, and sale of non-influenza Vaccines business Sharpens company focus on growing segments of innovative pharmaceuticals, eye care and generics Addition of GSK oncology products and two pipeline compounds is expected to expand Novartis position in targeted therapies and small […]

March 5, 2015 - 5 minutesmins - By Cédric Brock

News and Trends 26 Feb 2015

Unstoppable Ferring after the Acquisition of a novel Oral Drug Delivery Technology

Ferring Pharmaceuticals signed an agreement with South Korean CTCBIO to acquire rights to a novel oral drug delivery technology. The Swiss company is growing more and more rapidly with plenty of updates since the begining of the year. Ferring’s success in developing oral formulations for peptide drugs including the world’s first orally active peptide, desmopressin […]

February 26, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 Feb 2015

#BioFigures: 3,000 whole genomes sequenced to fight Parkinson!

WHO? 23andMe, founded in 2006, is the leading personal genetics company dedicated to helping people access, understand and benefit from the human genome. The vision for 23andMe is to personalize healthcare by making and supporting meaningful discoveries through genetic research. Photo credit: 23andMe WHAT? 23andMe, announced an agreement with Genentech, a member of the Swiss Roche Group, […]

February 18, 2015 - 2 minutesmins - By Marie Godar

News and Trends 14 Feb 2015

GlycoVaxyn: A new Gain for GSK’s Vaccines Business

GSK, who was already a minority shareholder in GlycoVaxyn, acquires the company and its biological conjugation platform which may help it to develop a new generation of prophylactic vaccines against bacterial infections. GSK has today paid €167M to purchase the remaining stake in the company. GlycoVaxyn’s innovative biological conjugation platform originates enables the development of […]

February 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 Jan 2015

Roche spent $1B for the Leading Molecular Information Biotech company: Foundation Medicine

2015 starts in a rush for the Biotech industry. Swiss Pharma-giant Roche just announced paying $1B to acquire 56% percent of leading molecular information and genomic analysis Biotech company Foundation Medicine. Foundation Medicine is a leading Biotech company in the field of molecular information and genomic analysis. It uses next-gen sequencing technology and solid bioinformatic analysis […]

January 13, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 9 Jan 2015

Will Nestlé lead the promising microbiome industry?

Nestlé is one of the food giants in the World. Last Tuesday, it made a huge step in the microbiome industry by investing $65M in Boston-based Seres Health, one of the most advanced Biotech start-ups in the field. Will Nestlé take control of the promising microbiome industry? Seres Health is a leading microbiome therapeutics platform company developing […]

January 9, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 15 Dec 2014

Will there be a New Merck-Serono?

GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought an option for €38M on the marketing rights outside the United States and Japan for a treatment against multiple sclerosis. Could GeNeuro become the next Merck-Serono? This amount will allow the Swiss company to continue the clinical development of this molecule. […]

December 15, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 8 Dec 2014

An Orphan Drug Status Granted for the Leading Telormedix’s Cancer Treatment

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and infectious diseases, has obtained the orphan drug designation to Vesimune for the treatment of carcinoma in situ (CIS) in the bladder, by the U.S. Food and Drug Administration (FDA). Vesimune (TMX-101), is a proprietary targeted small molecule for the treatment of […]

December 8, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 3 Dec 2014

New Technologies Against Allergies are on the Wave

Anergis, a company developing proprietary ultra-fast allergy vaccines, closed a Series B financing round totaling 12,1 million euros. Anergis is not the only company that focuses on allergies, DBV technologies also recently raised money for its new anti-allergic patch. Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world affecting over 500 million […]

December 3, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 14 Nov 2014

A Way to Control Genes within Human Brain?

Researchers at the Department of Biosystems in Basel have developed a novel gene regulation method that enables thought-specific brainwaves to control the conversion of genes into proteins, so the genes expression. It opens new ways to control gene expression within your brain and could lead to brain surgeries. In this new study, bioengineers placed implants inside […]

November 14, 2014 - 2 minutesmins - By Julie Lellouche

News and Trends 6 Nov 2014

The First Patient Receives an Implant Pump System to manage Pleural Effusions

For the first time, a pleurapump system designed to manage chronic pleural effusions was implanted in a patient in Marseille (France). This is an innovative device from Sequana Medical AG, a private Swiss medical device company. Chronic pleural effusions is recurrence of excess fluid which collects around the lungs. The most common causes of it are congestive heart […]

November 6, 2014 - 2 minutesmins - By Julie Lellouche

CSL pays 275m to acquire Novartis flu vaccines manufacturing sites strict xxl

News and Trends 31 Oct 2014

Novartis steps down completely from Vaccines’ Business

Novartis divests its influenza vaccines business to CSL Limited, an Australian company, for an agreed price of 219 million euros, completing the last deal with GSK a few months ago. This is a strategic move of Novartis; they plan to focus on the pharmaceutical business, ophthalmology (Alcon) and generics (Sandoz). Last year, influenza vaccine business reached a turnover of 1 […]

October 31, 2014 - 2 minutesmins - By Julie Lellouche

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Switzerland

Novartis announces completion of transactions with GSK

Unstoppable Ferring after the Acquisition of a novel Oral Drug Delivery Technology

#BioFigures: 3,000 whole genomes sequenced to fight Parkinson!

GlycoVaxyn: A new Gain for GSK’s Vaccines Business

Roche spent $1B for the Leading Molecular Information Biotech company: Foundation Medicine

Will Nestlé lead the promising microbiome industry?

Will there be a New Merck-Serono?

An Orphan Drug Status Granted for the Leading Telormedix’s Cancer Treatment

New Technologies Against Allergies are on the Wave

A Way to Control Genes within Human Brain?

The First Patient Receives an Implant Pump System to manage Pleural Effusions

Novartis steps down completely from Vaccines’ Business

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!